Cangrelor tetrasodium and Ravicti

• Generic Name: cangrelor
• Dosage Forms: n.a.
• Other Brand Names: Kengreal

Used as an adjunct to PCI to reduce the risk of periprocedural MI, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12-receptor antagonist and are not being given a glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor.

Dual-drug antiplatelet therapy with a P2Y12-receptor antagonist and aspirin is part of the current standard of care in patients with acute coronary syndromes (ACS).

Potential advantages of cangrelor include rapid onset and offset of effect and less interindividual variability in antiplatelet effect (i.e., compared with clopidogrel).

Precise role of cangrelor in the management of ACS remains to be established.

• Generic Name: glycerol phenylbutyrate
• Dosage Forms: oral liquid
• Other Brand Names: Ravicti

Ravicti (glycerol phenylbutyrate) binds with other substances in the liver and kidneys to help eliminate nitrogen from the body. Excess nitrogen can cause hyperammonemia, a build-up of ammonia in the blood. Ammonia is very toxic when it circulates in blood and tissues and can cause permanent brain damage, coma, or death.

Ravicti helps prevent a build-up of ammonia in the blood in people with urea cycle disorder. This medicine is used in adults, children and infants. Ravicti will not treat hyperammonemia.

Ravicti is usually given together with a low-protein diet and sometimes dietary supplements.